drugset / Trial / NCT04967833

A Study of GC101 TIL in Advanced Solid Tumors (TR)

NCT04967833

NaSingle-groupOpen-labelTreatment

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Timeline

Start
2021-04-22
Primary completion
2025-12-22
Completion
2026-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor Infiltrating Lymphocytes Cell therapy 1e+09 cells Intravenous
Subject Tumor Infiltrating Lymphocytes Cell therapy 5e+10 cells Intravenous

Indications